Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds
Cingulate Inc. (CING)
Company Research
Source: GlobeNewswire
KANSAS CITY, Kan., June 28, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (the “Company”) (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced the entry into definitive agreements for the immediate exercise of certain outstanding Series A warrants to purchase up to an aggregate of 2,125,000 shares of common stock of the Company and Series B warrants to purchase up to an aggregate of 1,062,500 shares of common stock of the Company originally issued in February 2023, having an exercise price of $2.00 per share, at a reduced exercise price of $0.585 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-1 (No. 333-276502). The offering is expected to close on or about July 1, 2024, subject to satisfaction of customary closing
Show less
Read more
Impact Snapshot
Event Time:
CING
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CING alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CING alerts
High impacting Cingulate Inc. news events
Weekly update
A roundup of the hottest topics
CING
News
- Cingulate Announces Exercise of Warrants for $1.86 Million Gross Proceeds [Yahoo! Finance]Yahoo! Finance
- Cingulate and ADHD Expert Dr. Ann Childress, MD to Participate in Benzinga All Live Access EventGlobeNewswire
- Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing Clearance [Yahoo! Finance]Yahoo! Finance
- Cingulate Achieves Key Manufacturing Milestone in the Development of its ADHD Drug CTx-1301 in Preparation for FDA Marketing ClearanceGlobeNewswire
- $10.9 Billion Attention Deficit Hyperactivity Disorder (ADHD) Opportunity Assessment and Forecasts 2022-2024 & 2032: Epidemiology, Symptoms, Diagnosis, Disease Management, Revenue, Unmet Needs [Yahoo! Finance]Yahoo! Finance
CING
Sec Filings
- 6/28/24 - Form DEF
- 6/27/24 - Form SC
- 6/18/24 - Form PRE
- CING's page on the SEC website